von Willebrand disease: proposing definitions for future research

Nathan T Connell¹, Paula D James², Romina Brignardello-Petersen³, Rezan Abdul-Kadir⁴, Barbara Ameer^{5

6}, Alice Arapshian⁷, Susie Couper⁸, Jorge Di Paola⁹, Jeroen Eikenboom¹⁰, Nicolas Giraud¹¹, Jean M Grow¹², Sandra Haberichter¹³, Vicki Jacobs-Pratt¹⁴, Barbara A Konkle^{15

16}, Peter Kouides¹⁷, Michael Laffan¹⁸, Michelle Lavin¹⁹, Frank W G Leebeek²⁰, Claire McLintock²¹, Simon McRae²², Robert Montgomery²³, Sarah H O'Brien²⁴, James S O'Donnell¹⁹, Margareth C Ozelo²⁵, Nikole Scappe²⁶, Robert Sidonio²⁷, Alberto Tosetto²⁸, Angela C Weyand²⁹, Mohamad A Kalot³⁰, Nedaa Husainat³⁰, Reem A Mustafa³⁰, Veronica H Flood²³

Affiliations

¹ Hematology Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
² Department of Medicine, Queen's University, Kingston, ON, Canada.
³ Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
⁴ The Royal Free Foundation Hospital and Institute for Women's Health, University College London, London, United Kingdom.
⁵ Pharmacology Consulting, Princeton Junction, NJ.
⁶ Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ.
⁷ Middle Village, NY.
⁸ Maylands, WA, Australia.
⁹ Department of Pediatrics, Washington University in St. Louis, St. Louis, MO.
¹⁰ Leiden University Medical Center, Leiden, The Netherlands.
¹¹ Marseille, France.
¹² Marquette University, Milwaukee, WI.
¹³ Versiti, Blood Research Institute and Diagnostic Labs, Milwaukee, WI.
¹⁴ Auburn, ME.
¹⁵ Bloodworks Northwest, Seattle, WA.
¹⁶ University of Washington, Seattle, WA.
¹⁷ University of Rochester, Mary M. Gooley Hemophilia Treatment Center, Rochester, NY.
¹⁸ Centre for Haematology, Imperial College London, London, United Kingdom.
¹⁹ Irish Centre for Vascular Biology, Royal College of Surgeons in Ireland, Dublin, Ireland.
²⁰ Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands.
²¹ National Women's Health, Auckland City Hospital, Auckland, New Zealand.
²² Northern Cancer Service, Launceston General Hospital, Launceston, TAS, Australia.
²³ Medical College of Wisconsin, Versiti Blood Research Institute, Milwaukee, WI.
²⁴ Division of Hematology/Oncology, Department of Pediatrics, Nationwide Children's Hospital, The Ohio State College of Medicine, Columbus, OH.
²⁵ Hemocentro UNICAMP, University of Campinas, Campinas, Sao Paulo, Brazil.
²⁶ Coraopolis, PA.
²⁷ Aflac Cancer and Blood Disorders, Children's Healthcare of Atlanta, Emory University, Atlanta, GA.
²⁸ Hemophilia and Thrombosis Center, Hematology Department, S. Bortolo Hospital, Vicenza, Italy.
²⁹ Divison of Hematology/Oncology, Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI; and.
³⁰ Outcomes and Implementation Research Unit, Division of Nephrology and Hypertension, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS.

PMID: 33496750
PMCID: PMC7839375
DOI: 10.1182/bloodadvances.2020003620

von Willebrand disease: proposing definitions for future research

Nathan T Connell et al. Blood Adv. 2021.

. 2021 Jan 26;5(2):565-569.

doi: 10.1182/bloodadvances.2020003620.

Authors

Affiliations

¹ Hematology Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
² Department of Medicine, Queen's University, Kingston, ON, Canada.
³ Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
⁴ The Royal Free Foundation Hospital and Institute for Women's Health, University College London, London, United Kingdom.
⁵ Pharmacology Consulting, Princeton Junction, NJ.
⁶ Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ.
⁷ Middle Village, NY.
⁸ Maylands, WA, Australia.
⁹ Department of Pediatrics, Washington University in St. Louis, St. Louis, MO.
¹⁰ Leiden University Medical Center, Leiden, The Netherlands.
¹¹ Marseille, France.
¹² Marquette University, Milwaukee, WI.
¹³ Versiti, Blood Research Institute and Diagnostic Labs, Milwaukee, WI.
¹⁴ Auburn, ME.
¹⁵ Bloodworks Northwest, Seattle, WA.
¹⁶ University of Washington, Seattle, WA.
¹⁷ University of Rochester, Mary M. Gooley Hemophilia Treatment Center, Rochester, NY.
¹⁸ Centre for Haematology, Imperial College London, London, United Kingdom.
¹⁹ Irish Centre for Vascular Biology, Royal College of Surgeons in Ireland, Dublin, Ireland.
²⁰ Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands.
²¹ National Women's Health, Auckland City Hospital, Auckland, New Zealand.
²² Northern Cancer Service, Launceston General Hospital, Launceston, TAS, Australia.
²³ Medical College of Wisconsin, Versiti Blood Research Institute, Milwaukee, WI.
²⁴ Division of Hematology/Oncology, Department of Pediatrics, Nationwide Children's Hospital, The Ohio State College of Medicine, Columbus, OH.
²⁵ Hemocentro UNICAMP, University of Campinas, Campinas, Sao Paulo, Brazil.
²⁶ Coraopolis, PA.
²⁷ Aflac Cancer and Blood Disorders, Children's Healthcare of Atlanta, Emory University, Atlanta, GA.
²⁸ Hemophilia and Thrombosis Center, Hematology Department, S. Bortolo Hospital, Vicenza, Italy.
²⁹ Divison of Hematology/Oncology, Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI; and.
³⁰ Outcomes and Implementation Research Unit, Division of Nephrology and Hypertension, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS.

PMID: 33496750
PMCID: PMC7839375
DOI: 10.1182/bloodadvances.2020003620

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interests.

References

1. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand’s disease. Blood. 1987;69(2):454-459. - PubMed
1. Bowman M, Hopman WM, Rapson D, Lillicrap D, James P. The prevalence of symptomatic von Willebrand disease in primary care practice. J Thromb Haemost. 2010;8(1):213-216. - PubMed
1. James PD, Connell NT, Ameer B, et al. . ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv. 2021;5(1):280-300. - PMC - PubMed
1. Connell NT, Flood VH, Brignardello-Peterson R, et al. . ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv. 2021;5(1):301-325. - PMC - PubMed
1. Castaman G, Lethagen S, Federici AB, et al. . Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood. 2008;111(7):3531-3539. - PubMed

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

von Willebrand disease: proposing definitions for future research

Affiliations

von Willebrand disease: proposing definitions for future research

Authors

Affiliations

Conflict of interest statement

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources